Search Results

You are looking at 11 - 20 of 106 items for :

  • "Bladder cancer" x
  • All content x
Clear All
Full access

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith

this activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Bladder Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Bladder Cancer

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

Bladder cancer is primarily seen among elderly individuals, with a median age at diagnosis of 73 years and most patients aged 65 to 85 years. It is the fourth leading cause of cancer-related death among men aged >80 years. 1 Thus, clinical care

Full access

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

treatment of invasive bladder cancer: Long-term results in 1,054 patients . J Clin Oncol 2001 ; 19 : 666 – 675 . 2 Vieweg J Gschwend JE Herr HW . Pelvic lymph node dissection can be curative in patients with node positive bladder cancer . J

Full access

John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick

A diagnosis of bladder cancer encompasses a wide variety of clinical entities, characterized by a range of genotypes and phenotypes, each with a unique susceptibility to various treatment modalities, rate of disease progression, and prognosis. The

Full access

The UNMC Eppley Cancer Center at The Nebraska Medical Center

An estimated 61,420 new cases of urinary bladder cancer will be diagnosed in the United States in 2006, making it the fourth most common cancer in men and the ninth most common neoplasm in women. Because the median age of diagnosis is 65 years, medical comorbidities are a frequent consideration. The clinical spectrum of bladder cancer can be divided into 3 categories: noninvasive tumors, invasive lesions, and metastatic lesions. These categories differ in prognosis, management, and therapeutic goals, and these guidelines discuss management strategies to achieve the best possible outcomes.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Thomas W. Flaig

“After decades without new bladder cancer treatments, in the past 2 years, and even more so in the past 6 to 9 months, approvals and clinical integration of new drugs have accelerated. We're finally getting traction against the disease,” according

Full access

Harry W. Herr

Non–muscle-invasive bladder cancers (NMIBCs) account for 75% of new cases. These include non–minimally invasive (Ta) and minimally invasive (T1) papillary tumors and flat carcinoma in situ (CIS). Papillary bladder tumors are classified as low

Full access

William C. Huang and Bernard H. Bochner

dissection, and bilateral uretero-enterostomy . J Urol 1950 ; 63 : 242 – 260 . 4. Mills RD Turner WH Fleischmann A . Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy

Full access

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman-Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Jonathan L. Wright, Lisa A. Gurski, and Alyse Johnson-Chilla

Overview An estimated 80,470 new cases of urinary bladder cancer (61,700 men and 18,770 women) will be diagnosed in the United States in 2019 with approximately 17,670 deaths (12,870 men and 4,800 women) occurring during this same period. 1 Bladder

Full access

S. Machele Donat

Cancer J Clin 2008 : 58 : 71 – 96 . 2 Stein JP Lieskovsky G Cote R . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients . J Clin Oncol 2001 ; 19 : 666 – 675 . 3 Dalbagni G Genega